Advertisement

Lung Cancer

  • Nicholas G. ZaorskyEmail author
  • Daniel M. Trifiletti
  • Henry WagnerJr
Chapter

Abstract

This chapter discusses the general management of patients with thoracic cancers, with special focus on principles that guide radiotherapy management. Several key components of trimodality care and stereotactic body radiation therapy (SBRT) are discussed.

Keywords

Non-small cell lung cancer Small cell lung cancer Thymoma Mesothelioma SBRT 

References

  1. 1.
    Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.PubMedCrossRefGoogle Scholar
  2. 2.
    Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141:662–70.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87:690–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Videtic GM, Hu C, Singh AK, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93:757–64.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Bylund A, Stattin P, Widmark A, et al. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol. 1998;49:143–8.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Cook B, DT. Wikibooks Radiation Oncology. https://en.wikibooks.org/wiki/Radiation_Oncology. Accessed April 2018.
  8. 8.
    Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2010.Google Scholar
  9. 9.
    Hansen E, Roach M. Handbook of evidence-based radiation oncology. 2nd ed. New York: Springer; 2010.CrossRefGoogle Scholar
  10. 10.
    Hristov B, Lin SH, Christodouleas JP. Radiation oncology - A question based review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2014.Google Scholar
  11. 11.
    Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically inoperable lung carcinoma: the role of radiation therapy. Semin Radiat Oncol. 1996;6:98–104.PubMedCrossRefGoogle Scholar
  13. 13.
    Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22; discussion 622-3.PubMedCrossRefGoogle Scholar
  15. 15.
    Moiseenko V, Liu M, Bergman AM, et al. Monte Carlo calculation of dose distribution in early stage NSCLC patients planned for accelerated hypofractionated radiation therapy in the NCIC-BR25 protocol. Phys Med Biol. 2010;55:723–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62:11–9.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Corradetti MN, Mitra N, Bonner Millar LP, et al. A moving target: image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer. Pract Radiat Oncol. 2013;3:307–15.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32:2456–62.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:1235–42.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Hiraki T, Tajiri N, Mimura H, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: incidence and risk factors. Radiology. 2006;241:275–83.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 1998;90:1335–45.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    D'Cunha J, Herndon JE 2nd, Herzan DL, et al. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005;48:241–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Mutter RW, Liu F, Abreu A, et al. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys. 2012;82:1783–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:796–801.PubMedCrossRefGoogle Scholar
  29. 29.
    Stephans KL, Djemil T, Reddy CA, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol. 2009;4:838–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Videtic GM, Stephans K, Reddy C, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys. 2010;77:344–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer. 2006;106:1347–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–51.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Spoelstra FO, Senan S, Le Pechoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys. 2010;76:1106–13.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005; CD002142.Google Scholar
  36. 36.
    PL03.05. An intergroup randomized phase III comparison of standard-dose (60 Gy) vs high-dose (74 Gy) chemoradiotherapy (CRT) +/− cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617. Clin Adv Hematol Oncol. 2014;12(2–4).Google Scholar
  37. 37.
    Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129–36.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–91.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543–55.PubMedCrossRefGoogle Scholar
  41. 41.
    Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29:272–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000;343:1217–22.PubMedCrossRefGoogle Scholar
  44. 44.
    Perez CA, Stanley K, Rubin P, et al. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1980;6:987–94.PubMedCrossRefGoogle Scholar
  45. 45.
    Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001;121:472–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64.PubMedCrossRefGoogle Scholar
  49. 49.
    Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636–48.PubMedCrossRefGoogle Scholar
  50. 50.
    van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–50.PubMedCrossRefGoogle Scholar
  51. 51.
    Weisenburger TH. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. LCSG 773. Chest. 1994;106:297S–301S.PubMedGoogle Scholar
  52. 52.
    Werner-Wasik M, Paulus R, Curran WJ Jr, et al. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer. 2011;12:245–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Stinchcombe TE, Hodgson L, Herndon JE, et al. Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009;4:1117–25.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Wang L, Wu S, Ou G, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77:89–96.PubMedCrossRefGoogle Scholar
  55. 55.
    Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015;33:567–74.PubMedCrossRefGoogle Scholar
  56. 56.
    Sundstrom S, Bremnes R, Aasebo U, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004;22:801–10.PubMedCrossRefGoogle Scholar
  57. 57.
    Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Eberhardt WE, Pottgen C, Gauler TC, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33:4194–201.PubMedCrossRefGoogle Scholar
  59. 59.
    Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 2012;84:456–63.PubMedCrossRefGoogle Scholar
  60. 60.
    Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol. 2007;30:239–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Xie L, Fan M, Sheets NC, et al. The use of radiation therapy appears to improve outcome in patients with malignant primary tracheal tumors: a SEER-based analysis. Int J Radiat Oncol Biol Phys. 2012;84:464–70.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Urdaneta AI, Yu JB, Wilson LD. Population based cancer registry analysis of primary tracheal carcinoma. Am J Clin Oncol. 2011;34:32–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3528–36.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092–9.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10:467–74.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.PubMedCrossRefGoogle Scholar
  71. 71.
    Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRefGoogle Scholar
  72. 72.
    Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42.PubMedCrossRefGoogle Scholar
  73. 73.
    Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–60.PubMedCrossRefGoogle Scholar
  74. 74.
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71.PubMedCrossRefGoogle Scholar
  75. 75.
    Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:943–51.PubMedCrossRefGoogle Scholar
  76. 76.
    Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5:592–600.PubMedCrossRefGoogle Scholar
  77. 77.
    Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 1994;12:496–502.PubMedCrossRefGoogle Scholar
  78. 78.
    Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85:1082–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179–82.PubMedCrossRefGoogle Scholar
  80. 80.
    Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer. 2011;12:375–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Brahmer JR, Ettinger DS. The Role of Topotecan in the Treatment of Small Cell Lung Cancer. Oncologist. 1998;3:11–4.PubMedGoogle Scholar
  82. 82.
    Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663–71.PubMedCrossRefGoogle Scholar
  83. 83.
    Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys. 2010;76:440–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Haniuda M, Miyazawa M, Yoshida K, et al. Is postoperative radiotherapy for thymoma effective? Ann Surg. 1996;224:219–24.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002;74:1033–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Mornex F, Resbeut M, Richaud P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys. 1995;32:651–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Wright CD. Management of thymomas. Crit Rev Oncol Hematol. 2008;65:109–20.PubMedCrossRefGoogle Scholar
  88. 88.
    Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg. 2008;85:385–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Hamaji M, Ali SO, Burt BM. A meta-analysis of induction therapy for advanced thymic epithelial tumors. Ann Thorac Surg. 2015;99:1848–56.PubMedCrossRefGoogle Scholar
  90. 90.
    Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–95.PubMedCrossRefGoogle Scholar
  91. 91.
    Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–95.PubMedCrossRefGoogle Scholar
  92. 92.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRefGoogle Scholar
  93. 93.
    Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16:1651–8.CrossRefGoogle Scholar
  94. 94.
    O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84:18–22.PubMedCrossRefGoogle Scholar
  95. 95.
    Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356:1862–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. J Clin Oncol. 1986;4:716–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicholas G. Zaorsky
    • 1
    Email author
  • Daniel M. Trifiletti
    • 2
  • Henry WagnerJr
    • 1
  1. 1.Penn State Cancer InstituteHersheyUSA
  2. 2.Mayo ClinicJacksonvilleUSA

Personalised recommendations